Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.000-6.250 for the period, compared to the consensus earnings per share estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Analyst Ratings Changes

A number of research firms have weighed in on LGND. Oppenheimer raised their price objective on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Barclays upped their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Benchmark restated a “buy” rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. Finally, Royal Bank of Canada upped their target price on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $147.00.

Ligand Pharmaceuticals Stock Down 3.3 %

NASDAQ LGND opened at $114.80 on Thursday. The company has a market cap of $2.17 billion, a PE ratio of 45.74 and a beta of 1.04. Ligand Pharmaceuticals has a 52 week low of $67.72 and a 52 week high of $129.90. The firm’s 50-day simple moving average is $113.99 and its two-hundred day simple moving average is $110.97.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.37 by ($3.01). Ligand Pharmaceuticals had a net margin of 29.68% and a return on equity of 4.95%. As a group, equities research analysts anticipate that Ligand Pharmaceuticals will post 1.73 EPS for the current year.

Insider Buying and Selling

In related news, CFO Octavio Espinoza sold 2,104 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $116.37, for a total transaction of $244,842.48. Following the transaction, the chief financial officer now directly owns 20,647 shares of the company’s stock, valued at approximately $2,402,691.39. This trade represents a 9.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.